Vivos Therapeutics Inc (NAS:VVOS)

$ 3.1 0.25 (8.8%) Market Cap: 14.77 Mil Enterprise Value: 8.39 Mil PE Ratio: 0 PB Ratio: 1.52 GF Score: 65/100

Q2 2024 Vivos Therapeutics Inc Earnings Call Transcript
Aug 14, 2024

$2.37 (+3.04%)

Earnings
Q1 2024 Vivos Therapeutics Inc Earnings Call Transcript
May 14, 2024

$2.49 (+23.88%)

Earnings
Q4 2023 Vivos Therapeutics Inc Earnings Call Transcript
Mar 28, 2024

$4.83 (+3.87%)

Earnings
Q3 2023 Vivos Therapeutics Inc Earnings Call Transcript
Nov 14, 2023

$3.73 (+9.71%)

Earnings
Q2 2023 Vivos Therapeutics Inc Earnings Call Transcript
Aug 16, 2023

$8.58 (+5.12%)

Earnings
Q1 2023 Vivos Therapeutics Inc Earnings Call Transcript
Jun 08, 2023

$11.75 (+13.25%)

Earnings
Q4 2022 Vivos Therapeutics Inc Earnings Call Transcript
Mar 30, 2023

$9 (+8.99%)

Earnings
Vivos Therapeutics Inc at Emerging Growth Conference (Virtual) Transcript
Feb 22, 2023
Vivos Therapeutics Inc Annual Shareholders Meeting Transcript
Aug 25, 2022
Q4 2021 Vivos Therapeutics Inc Earnings Call Transcript
Mar 31, 2022

$67 (+1.13%)

Earnings
Vivos Therapeutics Inc at Benzinga Global Small Cap Investor Conference (Virtual) Transcript
Dec 09, 2021
Q3 2021 Vivos Therapeutics Inc Earnings Call Transcript
Nov 15, 2021

$101.5 (+3.31%)

Earnings
Vivos Therapeutics Inc at Benzinga Global Small Cap Conference (Virtual) Transcript
Oct 27, 2021
Vivos Therapeutics Inc at Benzinga Healthcare Small Cap Conference (Virtual) Transcript
Sep 29, 2021
Q2 2021 Vivos Therapeutics Inc Earnings Call Transcript
Aug 12, 2021

$68.5 (-2.84%)

Earnings
Q1 2021 Vivos Therapeutics Inc Earnings Call Transcript
May 17, 2021

Earnings

Q2 2023 Vivos Therapeutics Inc Earnings Call Transcript

Aug 16, 2023 / 10:00PM GMT

Release Date Price: $8.58 (+5.12%)

Transcript 8-K10-Q

Operator

Good day, everyone and welcome to Vivos Therapeutics' second quarter earnings call. (Operator Instructions) This conference call is being recorded. And a replay of today's call will be available on the investor relation section of Vivo's website and will remain posted there for the next 30 days. I will now hand over the call to Julie Gannon, Vivos' Investor Relation officer for the introductions and the reading of the safe harbor statement. Please go ahead.

Julie Gannon

Vivos Therapeutics, Inc. - IR

Thank you, operator. Hello, everyone, and welcome to our conference call. A copy of our earnings press release is available on the Investor Relations section of our website at www.vivos.com. With us on today's call are Kirk Huntsman, Vivos Chairman and Chief Executive Officer, and Brad Amman, Chief Financial Officer.

Today, we'll review the highlights and financial results for the second quarter of 2023 as well as more recent developments and deals plans for the remainder of 2023. Following

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.